Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes
- PMID: 10340957
- PMCID: PMC1752903
- DOI: 10.1136/ard.58.6.335
Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Artérite à Cellules Géantes
Abstract
Objectives: To assess the clinical features of biopsy proven and negative biopsy temporal arteritis at the time of diagnosis and during a three year follow up.
Methods: Newly diagnosed cases of giant cell arteritis were included in a prospective, multicentre study. Initial clinical and biological features, season of diagnosis, and cardiovascular events occurring during the follow up were recorded. Biopsy proven and negative biopsy cases were compared.
Results: Two hundred and seven biopsy proven, and 85 negative biopsy cases were included from 1991 to 1997. Fifty eight per cent of the biopsy proven cases, compared with 39.29% of the negative biopsy cases, were diagnosed during the autumn or winter (p = 0.003). Visual problems (31.5%, v 19.1%, p = 0.031), blindness (9.7% v 2.38%, p = 0.033), jaw claudication (40.8%, v 28.243%, p = 0.044), and temporal artery palpation abnormalities (61.3% v 29.5%, p = 7.10(-7)) were more frequent in the biopsy proven than in the negative biopsy group. Less specific symptoms, such as headache (82.5% v 92. 9%, p = 0.021), or associated polymyalgia rheumatica (40.1% v 65.9%, p = 9 x 10(-5)) were more prevalent in the negative biopsy cases. Biological markers of inflammation were significantly more increased in the biopsy proven group. All cases of blindness occurring after treatment belonged to the biopsy proven group.
Conclusion: Biopsy proven cases seem to be more severe than biopsy negative cases at the time of diagnosis and during follow up. Seasonal difference at diagnosis may suggest a different aetiological pattern.
Similar articles
-
Giant cell arteritis, polymyalgia rheumatica, and viral hypotheses: a multicenter, prospective case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes.J Rheumatol. 1999 Feb;26(2):361-9. J Rheumatol. 1999. PMID: 9972970
-
Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Artérite à Cellules Géantes.Arthritis Rheum. 1998 Apr;41(4):701-9. doi: 10.1002/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P. Arthritis Rheum. 1998. PMID: 9550480 Clinical Trial.
-
Giant cell arteritis and polymyalgia rheumatica: are pregnancies a protective factor? A prospective, multicentre case-control study. GRACG (Groupe de Recherche sur l'Artérite à Cellules Géantes).Rheumatology (Oxford). 1999 Feb;38(2):118-23. doi: 10.1093/rheumatology/38.2.118. Rheumatology (Oxford). 1999. PMID: 10342623
-
[Giant cell arteritis. A study of 191 patients].Med Clin (Barc). 1995 Dec 2;105(19):734-7. Med Clin (Barc). 1995. PMID: 8523954 Review. Spanish.
-
Polymyalgia rheumatica and temporal arthritis.Am Fam Physician. 2000 Aug 15;62(4):789-96, 801. Am Fam Physician. 2000. PMID: 10969858 Review.
Cited by
-
Giant cell arteritis: epidemiology, diagnosis, and management.Curr Rheumatol Rep. 2010 Dec;12(6):436-42. doi: 10.1007/s11926-010-0135-9. Curr Rheumatol Rep. 2010. PMID: 20857242 Review.
-
Headache as the most common manifestation of giant cell arteritis?: a systematic review with meta-analysis.Rheumatol Int. 2025 Feb 11;45(3):47. doi: 10.1007/s00296-025-05803-9. Rheumatol Int. 2025. PMID: 39932568
-
Giant-cell arteritis without cranial manifestations: Working diagnosis of a distinct disease pattern.Medicine (Baltimore). 2016 Jun;95(26):e3818. doi: 10.1097/MD.0000000000003818. Medicine (Baltimore). 2016. PMID: 27367984 Free PMC article.
-
Necessity of Temporal Artery Biopsy for Giant Cell Arteritis: A Systematic Review.Plast Reconstr Surg Glob Open. 2022 May 20;10(5):e4185. doi: 10.1097/GOX.0000000000004185. eCollection 2022 May. Plast Reconstr Surg Glob Open. 2022. PMID: 35620490 Free PMC article.
-
Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?RMD Open. 2017 Mar 29;3(1):e000353. doi: 10.1136/rmdopen-2016-000353. eCollection 2017. RMD Open. 2017. PMID: 28405470 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical